# Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

> **NCT04070768** · PHASE1 · COMPLETED · sponsor: **John Quigley** · enrollment: 18 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Gemtuzumab Ozogamicin
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04070768
- **Lead sponsor:** John Quigley
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-06
- **Primary completion:** 2023-10-12
- **Final completion:** 2024-02-20
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04070768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04070768, "Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04070768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*